Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?

doi:10.1016/j.euros.2022.10.002

. 2022 Oct 25:46:39-42.

doi: 10.1016/j.euros.2022.10.002. eCollection 2022 Dec.

Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?

Michele Marchioni^{1

2}, Daniele Amparore^{1

3}, Laura Marandino^{1

4}, Riccardo Bertolo^{1

5}, Selcuk Erdem^{1

6}, Alexandre Ingels^{1

7}, Stijn Muselaers^{1

8}, Onder Kara^{1

9}, Nicola Pavan^{1

10}, Eduard Roussel^{1

11}, Umberto Carbonara^{1

12}, Angela Pecoraro^{1

13}, Pietro Diana^{1

14}, Alessio Pecoraro^{15

16}, Riccardo Campi^{1

15

16}; European Association of Urology Young Academic Urologists Renal Cancer Working Group

Affiliations

¹ European Association of Urology Young Academic Urologists Renal Cancer Working Group, Arnhem, The Netherlands.
² Department of Urology, SS Annunziata Hospital, G. D'Annunzio University of Chieti, Chieti, Italy.
³ Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
⁴ Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁵ Department of Urology, San Carlo Di Nancy Hospital, Rome, Italy.
⁶ Division of Urologic Oncology, Department of Urology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
⁷ Department of Urology, University Hospital Henri Mondor, APHP, Créteil, France.
⁸ Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁹ Department of Urology, Kocaeli University School of Medicine, Kocaeli, Turkey.
¹⁰ Urology Clinic, Department of Medical, Surgical and Health Science, University of Trieste, Trieste, Italy.
¹¹ Department of Urology, University Hospitals Leuven, Leuven, Belgium.
¹² Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.
¹³ Department of Urology, Pederzoli Hospital, Peschiera del Garda, Italy.
¹⁴ Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain.
¹⁵ Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
¹⁶ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

PMID: 36325369
PMCID: PMC9618788
DOI: 10.1016/j.euros.2022.10.002

Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?

Michele Marchioni et al. Eur Urol Open Sci. 2022.

. 2022 Oct 25:46:39-42.

doi: 10.1016/j.euros.2022.10.002. eCollection 2022 Dec.

Authors

Affiliations

¹ European Association of Urology Young Academic Urologists Renal Cancer Working Group, Arnhem, The Netherlands.
² Department of Urology, SS Annunziata Hospital, G. D'Annunzio University of Chieti, Chieti, Italy.
³ Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
⁴ Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁵ Department of Urology, San Carlo Di Nancy Hospital, Rome, Italy.
⁶ Division of Urologic Oncology, Department of Urology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
⁷ Department of Urology, University Hospital Henri Mondor, APHP, Créteil, France.
⁸ Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁹ Department of Urology, Kocaeli University School of Medicine, Kocaeli, Turkey.
¹⁰ Urology Clinic, Department of Medical, Surgical and Health Science, University of Trieste, Trieste, Italy.
¹¹ Department of Urology, University Hospitals Leuven, Leuven, Belgium.
¹² Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.
¹³ Department of Urology, Pederzoli Hospital, Peschiera del Garda, Italy.
¹⁴ Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain.
¹⁵ Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
¹⁶ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

PMID: 36325369
PMCID: PMC9618788
DOI: 10.1016/j.euros.2022.10.002

No abstract available

PubMed Disclaimer

Cited by

Impact of contrast enhancement phase on CT-based radiomics analysis for predicting post-surgical recurrence in renal cell carcinoma.
Khene ZE, Bhanvadia R, Tachibana I, Sharma P, Trevino I, Graber W, Bertail T, Fleury R, Acosta O, De Crevoisier R, Bensalah K, Lotan Y, Margulis V. Khene ZE, et al. Jpn J Radiol. 2025 Jun;43(6):977-984. doi: 10.1007/s11604-025-01740-6. Epub 2025 Feb 5. Jpn J Radiol. 2025. PMID: 39907976
Hypermethylated SHOX2 in circulating cell-free DNA post renal cell carcinoma surgery as TNM-independent biomarker for recurrence risk.
Büttner T, Zarbl R, Krausewitz P, Strieth S, Kristiansen G, Eckstein M, Ralser DJ, Hölzel M, Ritter M, Ellinger J, Dietrich D, Klümper N. Büttner T, et al. Am J Transl Res. 2024 Jan 15;16(1):304-313. doi: 10.62347/QOBT7285. eCollection 2024. Am J Transl Res. 2024. PMID: 38322559 Free PMC article.
Advances in Adjuvant Therapy for Renal Cell Carcinoma: Perspectives on Risk Stratification and Treatment Outcomes.
Furukawa J, Tomida R, Daizumoto K, Sasaki Y, Fukawa T. Furukawa J, et al. Int J Urol. 2025 Jul;32(7):781-790. doi: 10.1111/iju.70050. Epub 2025 Mar 24. Int J Urol. 2025. PMID: 40123286 Free PMC article. Review.

References

1. Choueiri T.K., Tomczak P., Park S.H., et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683–694. doi: 10.1056/NEJMoa2106391. - DOI - PubMed
1. Powles T., Tomczak P., Park S.H., et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:1133–1144. doi: 10.1016/S1470-2045(22)00487-9. - DOI - PubMed
1. Bedke J., Albiges L., Capitanio U., et al. 2021 updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma. Eur Urol. 2022;81:134–137. doi: 10.1016/j.eururo.2021.11.022. - DOI - PubMed
1. Powles T., Albiges L., Bex A., et al. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32:1511–1519. doi: 10.1016/j.annonc.2021.09.014. - DOI - PubMed
1. European Medicines Agency. CHMP post-authorisation summary of positive opinion for Keytruda (II-108). https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003....

LinkOut - more resources

Full Text Sources

[1] Choueiri T.K., Tomczak P., Park S.H., et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683–694. doi: 10.1056/NEJMoa2106391. - DOI - PubMed

[2] Choueiri T.K., Tomczak P., Park S.H., et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683–694. doi: 10.1056/NEJMoa2106391. - DOI - PubMed

[3] Powles T., Tomczak P., Park S.H., et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:1133–1144. doi: 10.1016/S1470-2045(22)00487-9. - DOI - PubMed

[4] Powles T., Tomczak P., Park S.H., et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:1133–1144. doi: 10.1016/S1470-2045(22)00487-9. - DOI - PubMed

[5] Bedke J., Albiges L., Capitanio U., et al. 2021 updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma. Eur Urol. 2022;81:134–137. doi: 10.1016/j.eururo.2021.11.022. - DOI - PubMed

[6] Bedke J., Albiges L., Capitanio U., et al. 2021 updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma. Eur Urol. 2022;81:134–137. doi: 10.1016/j.eururo.2021.11.022. - DOI - PubMed

[7] Powles T., Albiges L., Bex A., et al. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32:1511–1519. doi: 10.1016/j.annonc.2021.09.014. - DOI - PubMed

[8] Powles T., Albiges L., Bex A., et al. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32:1511–1519. doi: 10.1016/j.annonc.2021.09.014. - DOI - PubMed

[9] European Medicines Agency. CHMP post-authorisation summary of positive opinion for Keytruda (II-108). https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003....

[10] European Medicines Agency. CHMP post-authorisation summary of positive opinion for Keytruda (II-108). https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003....

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?

Affiliations

Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?

Authors

Affiliations

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources